Clinical data | |
---|---|
Routes of administration | IV |
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C11H22N6O |
Molar mass | 254.338 g·mol−1 |
3D model ( JSmol) | |
| |
|
ENA-001 (formerly GAL-021) [1] is a drug related to almitrine which acts as a respiratory stimulant, with its mechanism of action primarily thought to involve blocking the BKCa potassium channel, [2] although secondary mechanisms may also be involved. [3] It was developed by Galleon Pharmaceuticals, and is being tested in clinical trials for potential uses in post-operative care, [4] as well as more generally to counteract the respiratory depression which can be a side effect of opioid analgesic drugs. [5] [6] [7]
Clinical data | |
---|---|
Routes of administration | IV |
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C11H22N6O |
Molar mass | 254.338 g·mol−1 |
3D model ( JSmol) | |
| |
|
ENA-001 (formerly GAL-021) [1] is a drug related to almitrine which acts as a respiratory stimulant, with its mechanism of action primarily thought to involve blocking the BKCa potassium channel, [2] although secondary mechanisms may also be involved. [3] It was developed by Galleon Pharmaceuticals, and is being tested in clinical trials for potential uses in post-operative care, [4] as well as more generally to counteract the respiratory depression which can be a side effect of opioid analgesic drugs. [5] [6] [7]